About this trial
Evidence for the usefulness of the defibrillator in cases of preserved left ventricular ejection fraction and well-tolerated ventricular tachycardia (without cardiocirculatory arrest or syncope) is lacking, as no previous trials have included such patients. Additionally, sudden death in this particular population is low compared to other subgroups of patients with malignant ventricular arrhythmias.
On the other hand, numerous recent retrospective data show that ablation of ventricular tachycardia can reduce mortality, and also clearly reduces the number of recurrences in prospective studies.
Finally, a very low rate of sudden death was observed in a multicenter European retrospective study that we conducted, including patients with well-tolerated ventricular tachycardia in structural heart disease with minimally impaired ejection fraction and benefiting from ablation without implantation of defibrillator.
Eligibility criteria
Qualifiers
ischemic heart disease with history of infarction - LVEF> 35% (measured by MRI)
sustained monomorphic ventricular tachycardia - without history of syncope or cardiac arrest -
having signed informed consent
affiliated to a social security system
Disqualifiers
transient regressive cause of ventricular tachycardia
recent myocardial infarction (<2 months)
ventricular tachycardia by reentry from branch to branch
serious conduction disturbances (with indication of stimulation)
Trial design
Treatments tested in this trial
- Adverse events collection
- Quality of life questionnaire EQ-5D-5L
- Medical-economic evaluation